Luvometinib

CAS 2739690-43-6

MF C26H22F2IN5O4S MW665.5 g/mol

CHINA 2025, APPROVALS 2025

N-[3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxopyrido[2,3-d]pyridazin-8-yl]phenyl]cyclopropanesulfonamide

N-{3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxo-1,2,5,6-tetrahydropyrido[2,3-
d]pyridazin-8-yl]phenyl}cyclopropanesulfonamide
mitogen-activated protein kinase (MEK) inhibitor, antineoplastic, FCN 159, FCN-159, B2DYT4V89X

Luvometinib is a drug for the treatment of various types of cancer. It is a selective, orally administered inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/MEK2), developed by Fosun Pharma for the treatment of rare malignancies, especially those driven by abnormal abnormal mitogen-activated protein kinase (MAPK) activation.^[1][2]

In May 2025, it was approved in China for the treatment of histiocytic neoplasms such as Langerhans cell histiocytosis (LCH) and the genetic disease neurofibromatosis type 1 (NF1).^[2]

Luvometinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2, with potential antineoplastic activity. Upon administration, luvometinib selectively binds to and inhibits the activity of MEK1 and MEK2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.

Luvometinib is a small molecule drug. The usage of the INN stem ‘-tinib’ in the name indicates that Luvometinib is a tyrosine kinase inhibitor. Luvometinib is under investigation in clinical trial NCT07004075 (FCN-159 Monotherapy Versus Chemotherapy by Investigator’s Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration). Luvometinib has a monoisotopic molecular weight of 665.04 Da.

SYN

Example 6 [WO2014169843]

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014169843&_cid=P22-MLD4HW-79323-1

Example 8

N-(3-(6-allyl-3-ƒluoro-4-(2-ƒluoro-4-iodophenylamino)-1-methyl-2,5-dioxo-1,2,5,6- tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)cyclopropanesulƒonamide (8)

The title compound 8 was prepared following the same procedure as described for Example 5 by substituting methanesulfonyl chloride with cyclopropanesulfonyl chloride. MS-ESI (m/z): 666 [M + 1]⁺.

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=EP159733179&_cid=P22-MLD4C4-76451-1

Example 8

N-(3-(6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodophenylamino)-1-methyl-2,5-dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl)phenyl)cyclopropanesulfonamide (8)

[0136]  The title compound 8 was prepared following the same procedure as described for Example 5 by substituting methanesulfonyl chloride with cyclopropanesulfonyl chloride. MS-ESI (m/z): 666 [M + 1] ⁺.

PAT

• Protein kinase inhibitorsPublication Number: CN-106905316-BPriority Date: 2013-04-18Grant Date: 2021-06-01
• Certain protein kinase inhibitorsPublication Number: EP-2986611-B1Priority Date: 2013-04-18Grant Date: 2019-02-06
• Certain protein kinase inhibitorsPublication Number: US-10022374-B2Priority Date: 2013-04-18Grant Date: 2018-07-17

AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

References

1.  Cheng Y, Tian H (2017). “Current Development Status of MEK Inhibitors”. Molecules. 22 (10). Basel, Switzerland: 1551. doi:10.3390/molecules22101551. PMC 6151813. PMID 28954413.
2.  Keam SJ (2025). “Luvometinib: First Approval”. Drugs. 85 (9): 1177–1183. doi:10.1007/s40265-025-02217-6. PMID 40751881.

Clinical data
Trade names	复迈宁 (Fu Mainin)
Other names	FCN-159
Routes of administration	Oral
Identifiers
IUPAC name
CAS Number	2739690-43-6
PubChem CID	135210935
IUPHAR/BPS	13495
UNII	B2DYT4V89X
Chemical and physical data
Formula	C26H22F2IN5O4S
Molar mass	665.45 g·mol−1
3D model (JSmol)	Interactive image
SMILES
InChI

//////////luvometinib, CHINA 2025, APPROVALS 2025, antineoplastic, FCN 159, FCN-159, B2DYT4V89X, ANAX, PTFEON, ADVECT, BLUE JET

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

ADVERTISEMENT

Advect Process Systems Ltd.

https://advectprocess.com/

ADVECT PROCESS SYSTEMS CANADA LTD
51 Beechwood Rd., Cambridge, ON Canada N1S 3S1, Call Now +1 306 850 6737, Mail Now,  ask@advectprocess.com

ADVERTISEMENT

BLUE JET HEALTHCARE LTD, https://bluejethealthcare.com

Looking for a Reliable SNAC Manufacturer? Let’s Talk.

At Blue Jet Healthcare Ltd, we specialize in the scalable, high-purity production of SNAC—a critical excipient powering the next generation of oral peptide therapeutics.

With increasing demand for SNAC across global pharma pipelines, choosing the right manufacturing partner is essential. Quality, timelines, and consistency matter.

Phone No. +91 (22) 22075307 / +91 (22) 22071691

Business Development/ Contract Manufacturing: marketing1@bluejethealthcare.com, madhu.gautam71@gmail.com